CDMO Blog

Considerations for the Use of Stable Producer Lines in the Manufacturing of Lentiviral Vectors

A-cell-culture-plate-is-handled-by-a-scientist

In an introductory post on lentiviral vector (LVV) manufacturing for cell and gene therapies (CGTs) we touched upon the challenges with transfection-based protocols for producing LVVs at large scale. Here we will take a closer look at the use of stable producer cell lines as an alternative to transient transfection for the manufacture of LVVs.

Read More
Posted: Oct 30, 2019 3:04:35 PM

How to Scale-Up Lentiviral Vector Production Part 1: Considerations for Upstream Processing

Scientist working with bioreactor

Lentiviral vectors (LVV) are a key component in the production of cell and gene therapies. They are most often used to deliver genetic material that will modify cells and confer therapeutic properties. Today, even with the proliferation of cell and gene therapies in development, LVV is still produced using legacy methods employed in basic research. Overcoming technical challenges in the scale-up of LVV production is a major focus for the industry. Scalable LVV production platforms are critical for manufacturing affordable cell and gene therapies and making them more widely available. For an overview of LVV manufacturing and process optimization considerations see our previous post.

Read More
Posted: Oct 29, 2019 1:26:17 PM